🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

EUROPA trial NCT04134598 - Investigator meeting in Milan, Italy 🇮🇹 Amazing team work and good vibes charger, moving towards the first interim analysis 💪🏼💪🏼💪🏼 #breastcancer #radonc #medonc #OncoAlert OncoAlert Azienda Ospedaliero-Universitaria Careggi Università di Firenze

SENOMAC: cT1-T3 breast cancer w/ 1-2 SLN macrometastases -> SLN only vs completion ALND RT in 90% HR for recurrence or death of 0.89 (95% CI, 0.66 to 1.19) - favoring SLN only! More data for AxRT #radonc and omission of ALND! nejm.org/doi/full/10.10…

New standard of care is born in limited stage small cell lung carcinoma: chemo/RT followed by IO. RT dose could be 60-70 Gy QD or 45 Gy with SIB GTV to 54 Gy in 30 FX BID. It grows more and more like NSCLC,

Despite 5 yr follow-up, most #cancer #drugs granted accelerated approval did not demonstrate benefit in #OS or QoL in confirmatory trials #JAMA jamanetwork.com/journals/jama/…

📖DCIS: Balance between overtreatment and undertreatment The Lancet ✅A comprehensive review ➡️natural history of DCIS ➡️challenges in the detection and diagnosis ➡️prognostic and therapeutic biology ➡️tailored surgical management ➡️Radiotherapy ➡️Systemic treatment

This reminds me of the NEJM work randomizing early palliative care vs continued systemic therapy, palliative care conferred survival benefit nejm.org/doi/full/10.10…

📌 Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases 🧠 (The SYBRA Study) | npj Breast Cancer ⁦OncoAlert⁩ #OncoAlertAF nature.com/articles/s4152…

Hypofractionated #radiation therapy in early #breastcancer - 5-year results from UNICANCER HypoG-01 phase 3 trial #ESMO24 Non inferior as compared to 2Gy-fractionation: moderate hypofractionation preferred standard of care for nodal irradiation OncoAlert #OncoAlert #radonc

Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project - Cancer Treatment Reviews … Great team work! Congrats to all the co-authors cancertreatmentreviews.com/article/S0305-…

📌 The role of radiation therapy in the multidisciplinary management of male breast cancer: a systematic review and meta-analysis. OncoAlert #OncoAlertAF 🔗proud to share our research article: sciencedirect.com/science/articl… Agnese Prisco Maria Carmen De Santis Fiorenza De Rose Nadia Pasinetti

The Full Program for #SABCS24 is out SABCS Look who’s around… #radonc #medonc #surgonc #BreastCancer #OncoAlert OncoAlert Università di Firenze Azienda Ospedaliero-Universitaria Careggi sabcs.org/FullProgram

Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive #BreastCancer out in JCO study aimed to develop a tool called RSClinN+ to personalize recurrence risk and chemotherapy benefit predictions

Single-modality endocrine therapy versus #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #BreastCancer (EUROPA) The Lancet Oncology ▶️ Share Link – 50 days' free access to the article (Jan 31, 2025): authors.elsevier.com/a/1kFkd5EIIgPe…

doi.org/10. 1016/j.lanepe.2024. 101160

Check out this recent paper in Annals of Surgical Oncology on the Risk of Surgical Overtreatment in cN1 #BreastCancer Patients who Become ypN0 After Neoadjuvant Chemotherapy: SLNB Versus TAD 👉pubmed.ncbi.nlm.nih.gov/39633166/ Saskia Leonard Olga Kantor MD, MS, FACS Dr. E Mittendorf Anna Weiss Tari King MD

Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review is out! JAMA Oncology A robust clinical and analytical validation of biomarkers to ensure clinical utility for RT optimization is still needed ☢️ #radonc #OncoAlert OncoAlert ESTRO pubmed.ncbi.nlm.nih.gov/39820307/

We’ve just enrolled the last patient in the EUROPA trial! 926 patients recruited over 4 years across 20 centres An infinite thank you to all patients, investigators, and caregivers who made this incredible journey possible ❤️ OncoAlert #OncoAlert #BreastCancer #radonc #medonc

Regional nodal irradiation in negative nodal status and after primary systemic therapy - amazing teaching lecture by Philip Poortmans and Liesbeth Boersma #ESTRO25 #radonc #breastcancer OncoAlert #OncoAlert

🚨Birgitte Offersen reports on SKAGEN-1 trial of hypofractionation (40/15 vs 50/25) #ESTRO25 1. Safe: similar lymphedema 2. Effective: similar locoregional and distance recurrence, OS BUT increased #breastcancer mortality, across subgroups & w/o explanation. Discussions to follow…

What are the limits of treatment de-intensification in early stage breast cancer? How does de-intensification of one modality affect de-intensification of another modality? Read about it in the #RedJournal. Naamit Kurshan Gerber @profamthompson @jennishengMD tinyurl.com/redgerber1